News

Eli Lilly (LLY) Announces Positive Results For Jaypirca In Phase 3 Trial
Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...
Stock Markets Beware Summer Scares. What Microsoft Must Learn From Novo’s $75 Billion Crash.
China trade talks wrap up, Berkshire’s potential railroad deal, oil prices spike, and more news to start your day.
Medindia2h
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight
Disclaimer - All information and content on this site are provided for informational and educational purposes only. They should NOT be used for the diagnosis or treatment of any health-related ...
DelveInsight Business Research, LLP: Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...